RARβ Agonist Drug (C286) Demonstrates Efficacy in a Pre-clinical Neuropathic Pain Model Restoring Multiple Pathways via DNA Repair Mechanisms

Ítems similars

• RARβ Agonist Drug (C286) Demonstrates Efficacy in a Pre-clinical Neuropathic Pain Model Restoring Multiple Pathways via DNA Repair Mechanisms
  per: Goncalves, Maria B., et al.
  Publicat: (2019)
• Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury
  per: Goncalves, Maria B., et al.
  Publicat: (2019)
• Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review
  per: Borthwick, Alan D., et al.
  Publicat: (2020)
• Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” [Bioorg. Med. Chem. Lett. 29(8) (2019) 995–1000]
  per: Goncalves, Maria B., et al.
  Publicat: (2019)
• Neuronal RARβ Signaling Modulates PTEN Activity Directly in Neurons and via Exosome Transfer in Astrocytes to Prevent Glial Scar Formation and Induce Spinal Cord Regeneration
  per: Goncalves, Maria B., et al.
  Publicat: (2015)